RSV, vaccine
Study confirms RSV vaccine's protective power for seniors
A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization.
RSV Vaccine Shows Strong Protection for Older Adults
A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or needing intensive care unit support for severe complications.
RSV vaccine effective in preventing hospitalizations in older Americans
Today, The Lancet published the first real-world data analysis of respiratory syncytial virus (RSV) vaccine efficacy among older US adults in a large multistate study. The study shows the vaccine was 80% effective in protecting against hospitalizations and deaths during the 2023-2024 RSV season.
Study finds RSV vaccine highly effective in protecting older adults against severe disease, hospitalization and death
A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the RSV—short for respiratory syncytial virus—vaccine. VISION Network researchers report that across the board these vaccines were highly effective in older adults,
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% effective in preventing severe illness three years after patients 60 and older first received the shot.
Abrysvo Vaccine Highly Effective Against RSV-Related Hospitalization in Older Adults
The RSV vaccine Abrysvo was highly effective against hospital and ED encounters in a large cohort of older adults with comorbidities and immunocompromising conditions.
GlobalData on MSN11h
MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win
MSD (Merck & Co) is planning to get its respiratory syncytial virus (RSV) vaccine, clesrovimab, approved and launched before ...
infectiousdiseaseadvisor.com16h
Investigational RSV Vaccine mRNA-1345: Revaccination Safe in Eligible Older Adults
There were no safety concerns identified among older adults following revaccination with the investigational respiratory syncytial virus vaccine mRNA-1345, and immune responses elicited by ...
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
McKnight's Long-Term Care News1d
Vaccine about 80 percent effective against severe RSV, hospitalization and death
The respiratory syncytial virus (RSV) vaccines were about 80% effective in older adults during the 2023-24 respiratory disease season, which was the first season after the shot was approved in the US, ...
Low RSV and COVID vaccine usage is in line with investor expectations, but concerning: Jefferies
Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...
dermatologyadvisor3d
RSV Vaccine Is Recommended for Long-Term Care Facility Residents
The RSV vaccine is unequivocally recommended for adults who are residents in skilled nursing and assisted living facilities.
SchaeffersResearch.com2d
3 Vaccine Stocks to Watch as Flu Season Approaches
Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring. Earlier today, ...
WA could be better protected against RSV this winter. Here’s why
Respiratory virus season is underway, but Washington is more prepared than it was last year to protect against some severe ...